RxDoctor Payments DataLook up a doctor →

Edward Rubin, MD

Pain Medicine · New Hyde Park, NYNPI 1174563431

Payments from drug & device makers

$57,937in general payments, 2019–2025

Across 711 payments — averaging $81.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertos Medical, Inc.$14K
  • MDD US Operations, LLC$12K
  • Indivior Inc.$11K
  • Boston Scientific$10K
  • Nevro Corp.$2K
  • Relievant Medsystems, Inc.$956
  • plus $8K from 49 others

What the payments were for

  • Consulting fees$13,80029%
  • Speaking & faculty fees$17,00036%
  • Travel & lodging$1,4073%
  • Food & beverage$14,86632%
  • Education$80%
  • Gifts$00%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,937 in reported general payments places this provider in the 95th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$1,326,307
Medicare patients
1,138
Services billed
24,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl24$31,661
Nucynta ErTapentadol Hcl13$14,989
Diclofenac Sodium48$12,924
Xtampza ErOxycodone Myristate20$12,341
Buprenorphine35$9,759
Oxycodone Hcl315$6,897
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen303$5,410
Pregabalin166$5,009
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl35$4,581
Lidocaine42$3,693
Gabapentin270$2,790
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen131$2,095
Morphine Sulfate ErMorphine Sulfate64$1,571
Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol15$1,457
Hydromorphone Hcl65$991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er$588$27,33033 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate$203$14,49484 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 pain medicine providers in New York.

Other pain medicine in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →